BiotechTV’s Brad Loncar interviews A. Katopodis on ways to solve T-cell exhaustion
For the full story, please, check out this link to Biotech TV and to find out more about Brad find him on LinkedIn.
Latest News
18.12.2024
Anaveon appoints Dr. Richard Sachse as Chief Medical Officer
Basel, December 18, 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer effective February 1, 2025. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and…Read more
07.11.2024
Anaveon presents new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Basel, Novmeber 9, 2024 – Anaveon, a clinical stage, immuno-oncology company, presents posters on ANV700 and ANV600 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held from Friday, November 8, 2024, to Sunday, November 10, 2024, in Houston, Texas. Abstracts will…Read more
30.10.2024
Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
— First presentation of ANV700, a targeted IL-21 employing proximity activated potentiation of cytokine signaling — — New mechanistic data provide insights into the mode of action of ANV600, currently in clinical development — Basel, October 30, 2024 – Anaveon, a clinical stage, immuno-oncology company,…Read more
Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com